Trastuzumab - an overview

Trastuzumab - an overview trastuzumab Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2 Trastuzumab uses multiple mechanisms to interfere with HER2 downstream trastuzumab On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo,

trastuzumab Trastuzumab injection products may cause serious or life-threatening reactions that may occur while the medication is being given or up to 24

trastuzumab Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and